eligibility_summary
Inclusion: Adults ≥18 with CD20+ DLBCL/PMBCL or transformed indolent B‑cell lymphoma, ECOG 0–2, received axi‑/tisa‑/liso‑cel and in PR at day 30±7. Labs: ANC≥1000, Plt≥50k, Hgb≥7 (≥8 if symptomatic), bili≤1.5×ULN (≤5× liver), AST/ALT≤3× (≤5× liver), CrCl≥45. WOCBP negative test. Exclusion: bulky ≥7.5 cm, PD/SD/CR, prior CD20×CD3 or anti‑CD20 ≤4 wks, ongoing/grade 4 CRS/ICANS, CNS involvement, active infection or cardiac/CNS/psych disease, other cancer <2 y, pregnant/nursing or no contraception.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II randomized trial (NCT06238648) in aggressive B‑cell lymphomas with partial response after CD19 CAR‑T. Intervention: epcoritamab, a subcutaneous CD20×CD3 bispecific T‑cell–engaging antibody (biologic), vs observation. Mechanism: simultaneously binds CD20 on malignant B cells and CD3 on T cells, creating an immune synapse that activates TCR/CD3 signaling, drives T‑cell proliferation and cytotoxic degranulation (perforin/granzymes), and induces targeted B‑cell killing/aplasia. Targets: CD20+ B‑cell lymphoma cells (DLBCL, PMBCL, transformed indolent lymphomas) and CD3+ effector T cells. Key pathways/cells: CD20 surface antigen, TCR/CD3 activation cascade, immune synapse formation, T‑cell–mediated cytotoxicity. Comparator: observation per standard care. Goal: increase complete response vs observation, dosing weekly → biweekly → monthly up to 12 cycles.